Portfolio company
Oncoliq
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops liquid biopsy tests using molecular biology and machine learning for early cancer detection in clinical and screening settings.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Epiliquid
This company develops blood-based liquid biopsy tests for early cancer detection and monitoring, serving clinical laboratories and medical practitioners.
Single molecule diagnostics
This company develops prenatal screening and oncology liquid biopsy tests for clinicians to identify genetic risks and monitor cancer treatments in patients.
LiquidCell Dx
This company develops blood-based liquid biopsy tests for tumor microenvironment profiling to help pharmaceutical companies and clinical partners predict cancer therapy responses.
Amadix
This company develops blood-based liquid biopsy tests for the early detection of colorectal, lung and pancreatic cancer in patients and healthcare settings.
Molecular Stethoscope
This company develops blood-based liquid biopsy tests that analyse cell-free messenger RNA to help clinicians and researchers detect and monitor diseases.
Infiniplex
This company develops liquid biopsy solutions using blood tests to monitor genetic biomarkers for cancer screening and precision oncology decisions for healthcare providers.
Avant Genomics
The company develops an automated platform for liquid biopsy sample preparation to assist clinical laboratories in cancer detection and monitoring.
OXCan
This company develops blood tests using proteomics and machine learning to enable early cancer detection for healthcare providers and patients.
